-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – PRV-3279 in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRV-3279 in Systemic Lupus Erythematosus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PRV-3279 in Systemic Lupus ErythematosusDrug Details:PRV-3279 (MGD-010) is under development for the...
-
Product Insights
Auto-Immune Diseases Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Auto-immune diseases Pipeline Market Report Overview Auto-immune diseases are used for detection of autoimmune disorder by identifying auto-antibodies in the patient’s test sample. The auto-immune diseases pipeline market research report provides a comprehensive understanding of the pipeline products and their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Territories ·       The...
-
Company Profile
Provention Bio Inc – Company Profile
Provention Bio Inc (Provention) is a clinical-stage biopharmaceutical company. It develops novel therapeutics for intercepting and preventing immune-mediated diseases. The company’s pipeline product portfolio includes PRV-031 teplizumab for the treatment of type one diabetes (T1D); PRV-015 is an anti-IL-15 monoclonal antibody for gluten-free diet non-responsive celiac disease (NRCD). It also develops PRV-3279 for preventing immunogenicity and SLE; PRV-101 is a polyvalent coxsackievirus B (CVB) vaccine developed for treating type one diabetes (T1D). Provention has licensing and co-development agreement with pharmaceutical...
Add to Basket -
Product Insights
Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
AML Pipeline Products Market Report Overview Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the bloodstream and spread to the other parts of the body. Symptoms of AML include fatigue, fever, bleeding, breathing problems, and weight loss. The predisposing factors involved are exposed to...
-
Product Insights
Net Present Value Model: Teplizumab
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Teplizumab Drug Details Teplizumab (MGA031) is...
-
Product Insights
Net Present Value Model: PRV-3279
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model PRV-3279 Drug Details PRV-3279 (MGD-010) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – PRV-101
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry PRV-101 Drug Details PRV-101 is under development for the prevention of Coxsackie virus B...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – edicotinib
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry edicotinib Drug Details Edicotinib (PRV-6527, JNJ-40346527) is under development for the treatment of relapsed...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – teplizumab
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry teplizumab Drug Details Teplizumab (MGA031) is under development for the treatment of type 1...